Lilly Reports Clinical Remission in 50% of Patients Treated with Mirikizumab in P-III (LUCENT-2) Trial for the Treatment of Ulcerative Colitis
Shots:
- The P-III (LUCENT-2) maintenance study evaluated the safety & efficacy of mirikizumab vs PBO in 365 active ulcerative colitis patients with 12wks completion of LUCENT-1 study, require maintenance therapy & with previously failed conventional/biologic therapies/JAK inhibitors
- The results demonstrated superior endpoints of mirikizumab vs PBO as 50% (~182/365) vs 25.1% (~45/179) of patients achieved clinical remission in 1yr. with the maintenance of clinical remission in 63.6% (~91/143) vs 36.9% (~24/65)
- The study showed a constant OS & fewer AEs vs PBO. Additionally, Lilly has submitted a BLA to the US FDA & an MAA in the EU for the approval of mirikizumab with regulatory decisions expected in 2023
Ref: PRNewswire | Image: Lilly
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
